Pfizer
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Pfizer sits in the top decile of US sponsors by registered trial count (#7 of 15,742 sponsors by registered trial count).
Pfizer: 1,845 sponsored US clinical trials, 106 recruiting.
Pfizer sponsors 1,845 registered US clinical trials on ClinicalTrials.gov, 106 of them currently recruiting, and 1,335 completed. 504 of these trials are in Phase 3-4 (later-stage) and 1,173 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 44 trials.
Top-decile sponsor footprint
Pfizer ranks in the top decile of sponsors by registered trial count (#7 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,335 of 1,673 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,845 total, page 25 of 37
Muscle Malonyl Coa Biomarker Assay Development
NCT01003444
A Study To Establish The Effects Of PF-04457845 On Sleep In Healthy Volunteers
NCT01002625
A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia
NCT00977522
Tanezumab In Osteoarthritis Of The Hip Or Knee
NCT00985621
Open Label Extension In Cancer Patients
NCT00830180
A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease
NCT00988598
A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis
NCT00938587
Genotropin Study Assessing Use of Injection Pen
NCT00965484
A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)
NCT00988624
Effect of Aricept on Biomarkers (Acetylcholine, sAPP Alpha) In Cerebrospinal Fluid
NCT00987220
A Phase 1 Single-Dose Escalation Study of PF-04308515 in Healthy Volunteers
NCT00990015
Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors
NCT00960440
A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin
NCT00990613
A Study To Explore The Effect On Inflammatory Markers After Nasal Allergen Challenge In Subjects With Seasonal Allergic Rhinitis And The Effect Of A Single Dose Of Ibuprofen Or Fluticasone Propionate On The Allergen Response.
NCT01064726
Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy
NCT00935012
Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy
NCT00974311
A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease
NCT00930059
Study Evaluating Safety, Tolerability, And Action Of OAP-189 In Subjects With Type 2 Diabetes On Metformin
NCT00970593
A Midazolam Drug Interaction Study With PF-04171327
NCT00987038
A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder
NCT00928070
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
NCT00932893
Phase 1, Single and Multiple Doses Study of Sitaxentan in Japanese and Western Subjects
NCT00981968
A Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-03882845 In Healthy Volunteers
NCT00971802
A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease
NCT00912288
Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia
NCT00886743
An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease
NCT00939783
Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer
NCT00959946
This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors
NCT00932126
A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors
NCT00915278
A Study to Investigate the Effect of ICA-105665 in Photosensitive Epilepsy Patients
NCT00979004
A Study Of Kappa Opioid Receptor Occupancy Of PF-04455242, Using PET (Positron Emission Tomography)
NCT00939887
A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
NCT00982657
Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
NCT00920816
Long Term Safety Study of Tanezumab in Chronic Low Back Pain
NCT00924664
Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis
NCT00925002
Study Of Single Ascending And Multiple Doses Of PF-04447943 In Japanese Subjects.
NCT00959803
A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers
NCT00959426
Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer
NCT00835978
A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency
NCT00911937
Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients
NCT00952380
Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma
NCT00868608
Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer
NCT00880009
The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
NCT00914667
A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers
NCT00931073
Relative Drug Exposures Of Two Formulations of PF-02341066
NCT00939731
A Pharmacokinetic And QT Study Of CP-751,871 In Healthy Subjects
NCT00926263
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
NCT00960531
A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1
NCT00824369
A Trial In Patients With Advanced Cancer And Leukemia
NCT00878189
Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis
NCT00883896
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 703 |
| Phase 2 | 470 |
| Phase 3 | 411 |
| Phase 4 | 93 |
Therapeutic Areas
What is open in the Pfizer pipeline
106 recruiting of 1,845 indexed (6% open); 1,335 completed (72%).
Phase mix: 504 late (III/IV) vs 1,173 early (I/II) (early-phase heavy).
Top condition: Healthy (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Pfizer: open-pipeline peers nationwide
Peers matched on 1,845 registered trials and 6% open enrollment, not the therapeutic-area sidebar.
Pfizer sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,845 trials (± recruiting share)
- Memorial Sloan Kettering Cancer Center · 1,884 trials · 17% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- Duke University · 1,725 trials · 11% recruiting
- University of California, San Francisco · 1,713 trials · 16% recruiting
Sponsors near 6% open enrollment (± trial volume)
- Pacira Pharmaceuticals · 6% recruiting · 88 trials
- BioDelivery Sciences International · 6% recruiting · 17 trials
- Colgate Palmolive · 6% recruiting · 51 trials
- Durham VA Medical Center · 6% recruiting · 17 trials
Related
What to do with this Pfizer page
1,845 registered trials is a research-attention snapshot, not an endorsement of Pfizer or any single study.
- 106 of Pfizer's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Pfizer studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Pfizer pipeline card: 1,845 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.